Humanized Antibody Market Report 2026

The humanized antibody market size has grown rapidly in recent years. It will grow from $39.7 billion in 2025 to $44.87 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to advancements in monoclonal antibody engineering, early clinical success of antibody therapies, expansion of oncology drug development, increasing biologics manufacturing capacity, growth of translational research programs.

The humanized antibody market size is expected to see rapid growth in the next few years. It will grow to $72.47 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to increasing demand for personalized cancer therapies, rising investments in next-generation biologics, expansion of autoimmune and infectious disease indications, growing adoption of precision medicine approaches, increasing regulatory approvals for antibody-based drugs. Major trends in the forecast period include increasing development of targeted antibody therapies, rising focus on reducing immunogenicity in biologics, growing adoption of antibody drug conjugates, expansion of bispecific and multispecific antibody formats, enhanced emphasis on precision oncology applications.

The increasing prevalence of infectious diseases is expected to drive the growth of the humanized antibody market in the coming years. Infectious diseases are caused by pathogenic microorganisms, including bacteria, viruses, fungi, or parasites, which can be transmitted directly or indirectly between individuals. The incidence of these diseases is rising due to factors such as increased global travel, which accelerates the spread of pathogens across regions. Humanized antibodies support the treatment of infectious diseases by providing targeted immune responses, making them effective against specific pathogens. They minimize the risk of immune rejection by closely mimicking natural human antibodies, enhancing both safety and therapeutic efficacy. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England rose to 4,850 in 2023, a 10.7% increase from 4,380 cases in 2022. Therefore, the rising prevalence of infectious diseases is fueling the growth of the humanized antibody market.

Leading companies in the humanized antibody market are focusing on developing innovative therapies, such as humanized bispecific antibodies, to expand labelable indications and provide stronger, more durable antitumor effects. Humanized bispecific antibodies are engineered to simultaneously bind two different antigens or two distinct epitopes on the same antigen while being modified to closely resemble natural human antibodies. For instance, in November 2024, Jazz Pharmaceuticals plc, an Ireland-based biopharmaceutical company, received accelerated FDA approval for Ziihera (zanidatamab-hrii) in the U.S. for previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer. This therapy is a humanized, IgG-like, bispecific HER2-directed antibody that binds two extracellular HER2 sites. It uses a proprietary mechanism to engage immune effector cells and directly induce apoptosis in cancer cells, enabling targeted elimination of malignant cells without requiring prior immune activation.

In September 2024, Valerio Therapeutics S.A., a France-based clinical-stage biotechnology company, acquired Emglev Therapeutics for an undisclosed amount. Through this acquisition, Valerio Therapeutics aims to enhance its antibody discovery capabilities by incorporating Emglev Therapeutics’ humanized single-domain antibody (sdAb) technology to accelerate the development of next-generation therapeutic candidates across multiple disease areas. Emglev Therapeutics, also based in France, specializes in the development of humanized single-domain antibodies (sdAbs).

Major companies operating in the humanized antibody market are Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Genmab A/S, Xencor Inc., Zymeworks Inc., MacroGenics Inc.

North America was the largest region in the humanized antibody market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the humanized antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the humanized antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the humanized antibody market by increasing costs of imported cell culture media, bioprocessing equipment, purification systems, and analytical instruments used in antibody development and manufacturing. Biopharmaceutical companies in North America and Europe are most affected due to reliance on global supply chains, while Asia-Pacific faces cost pressure on biologics export manufacturing. These tariffs can increase production costs and slow scale-up activities. However, they also support regional biologics manufacturing investments, domestic supply chain strengthening, and innovation in cost-efficient antibody production technologies.

The humanized antibody market research report is one of a series of new reports that provides humanized antibody market statistics, including humanized antibody industry global market size, regional shares, competitors with a humanized antibody market share, detailed humanized antibody market segments, market trends and opportunities, and any further data you may need to thrive in the humanized antibody industry. This humanized antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Humanized antibody is a type of monoclonal antibody engineered to closely resemble human antibodies while maintaining the antigen-binding specificity of the original non-human antibody. It is created by replacing most of the non-human antibody’s protein sequences with corresponding human sequences, reducing the risk of immune reactions. These antibodies are widely used in research and therapy to target specific molecules with high precision and lower immunogenicity.

The main antibody types within humanized antibodies include humanized antibodies, chimeric antibodies, fully human antibodies, and murine antibodies. Humanized antibodies are laboratory-engineered antibodies originally derived from non-human species, in which most of the molecular structure is substituted with human antibody components while retaining only the antigen-binding regions required for target recognition. Product types include monoclonal antibodies, polyclonal antibodies, and antibody-drug conjugates. They are applied in areas such as cancer, autoimmune diseases, infectious diseases, and cardiovascular diseases, serving end-users like hospitals, research institutes, diagnostic laboratories, and others.

The humanized antibody market consists of sales of humanized bispecific antibodies, humanized antibody fragments, humanized antibody libraries, and antibody humanization kits and reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.